These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21655905)

  • 1. Differentiation of malignant from benign heart and pericardial lesions using positron emission tomography and computed tomography.
    Shao D; Wang SX; Liang CH; Gao Q
    J Nucl Cardiol; 2011 Aug; 18(4):668-77. PubMed ID: 21655905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT.
    Rahbar K; Seifarth H; Schäfers M; Stegger L; Hoffmeier A; Spieker T; Tiemann K; Maintz D; Scheld HH; Schober O; Weckesser M
    J Nucl Med; 2012 Jun; 53(6):856-63. PubMed ID: 22577239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.
    Tian R; Su M; Tian Y; Li F; Li L; Kuang A; Zeng J
    Skeletal Radiol; 2009 May; 38(5):451-8. PubMed ID: 19205695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
    Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of solitary thyroid nodule on 18F-FDG PET/CT and high-resolution ultrasonography.
    D'Souza MM; Marwaha RK; Sharma R; Jaimini A; Thomas S; Singh D; Jain M; Bhalla PJ; Tripathi M; Tiwari A; Mishra A; Mondal A; Tripathi RP
    Ann Nucl Med; 2010 Jun; 24(5):345-55. PubMed ID: 20373060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Respiratory-gated imaging in metabolic evaluation of small solitary pulmonary nodules: 18F-FDG PET/CT and correlation with histology.
    Farid K; Poullias X; Alifano M; Regnard JF; Servois V; Caillat-Vigneron N; Petras S
    Nucl Med Commun; 2015 Jul; 36(7):722-7. PubMed ID: 25793929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules.
    Takanami K; Hiraide T; Tsuda M; Nakamura Y; Kaneta T; Takase K; Fukuda H; Takahashi S
    Ann Nucl Med; 2011 Aug; 25(7):501-10. PubMed ID: 21537945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation between malignancy and inflammation in pulmonary ground-glass nodules: The feasibility of integrated (18)F-FDG PET/CT.
    Chun EJ; Lee HJ; Kang WJ; Kim KG; Goo JM; Park CM; Lee CH
    Lung Cancer; 2009 Aug; 65(2):180-6. PubMed ID: 19155090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of SUV(max) obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation.
    Hu SL; Yang ZY; Zhou ZR; Yu XJ; Ping B; Zhang YJ
    Nucl Med Commun; 2013 Jun; 34(6):533-9. PubMed ID: 23503000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of MR imaging and FDG-PET/CT in the differential diagnosis of benign and malignant vertebral compression fractures.
    Cho WI; Chang UK
    J Neurosurg Spine; 2011 Feb; 14(2):177-83. PubMed ID: 21214309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (18)F-FDG PET-CT respiratory gating in characterization of pulmonary lesions: approximation towards clinical indications.
    García Vicente AM; Soriano Castrejón AM; Talavera Rubio MP; León Martín AA; Palomar Muñoz AM; Pilkington Woll JP; Poblete García VM
    Ann Nucl Med; 2010 Apr; 24(3):207-14. PubMed ID: 20177834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solid splenic masses: evaluation with 18F-FDG PET/CT.
    Metser U; Miller E; Kessler A; Lerman H; Lievshitz G; Oren R; Even-Sapir E
    J Nucl Med; 2005 Jan; 46(1):52-9. PubMed ID: 15632034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The additional value of CT images interpretation in the differential diagnosis of benign vs. malignant primary bone lesions with 18F-FDG-PET/CT.
    Strobel K; Exner UE; Stumpe KD; Hany TF; Bode B; Mende K; Veit-Haibach P; von Schulthess GK; Hodler J
    Eur J Nucl Med Mol Imaging; 2008 Nov; 35(11):2000-8. PubMed ID: 18712385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of ¹⁸F-FDG PET/CT in differentiation of a benign lesion and metastasis on the ribs of cancer patients.
    Choi HS; Yoo IeR; Park HL; Choi EK; Kim SH; Lee WH
    Clin Imaging; 2014; 38(2):109-14. PubMed ID: 24361174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of solitary pulmonary nodules with 18F-FDG PET/CT relative activity distribution analysis.
    Zhao L; Tong L; Lin J; Tang K; Zheng S; Li W; Cheng D; Yin W; Zheng X
    Eur Radiol; 2015 Jul; 25(7):1837-44. PubMed ID: 25636419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG-PET/CT for diagnosis of primary ovarian cancer.
    Kitajima K; Suzuki K; Senda M; Kita M; Nakamoto Y; Onishi Y; Maeda T; Yoshikawa T; Ohno Y; Sugimura K
    Nucl Med Commun; 2011 Jul; 32(7):549-53. PubMed ID: 21407140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic usefulness of FDG PET for pancreatic mass lesions.
    Koyama K; Okamura T; Kawabe J; Nakata B; Chung KH; Ochi H; Yamada R
    Ann Nucl Med; 2001 Jun; 15(3):217-24. PubMed ID: 11545191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total lesion glycolysis as the best 18F-FDG PET/CT parameter in differentiating intermediate-high risk adrenal incidentaloma.
    Kim YI; Cheon GJ; Paeng JC; Cho JY; Kang KW; Chung JK; Kim EE; Lee DS
    Nucl Med Commun; 2014 Jun; 35(6):606-12. PubMed ID: 24598843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.